Preeclampsia: RNA Blood Test for Pregnancy Complication
Blood Test Shows Promise in predicting Preeclampsia
Table of Contents
Obstetricians are constantly seeking ways to detect preeclampsia early or even predict which pregnant women are likely to develop the condition.
Preeclampsia, characterized by high blood pressure and elevated protein levels in urine, poses a serious medical emergency, endangering both the mother and the unborn child.
Early Detection Through Molecular Signals
Researchers have reported discovering a molecular signal in pregnant women’s blood samples that could predict the risk of preeclampsia and related complications months before symptoms appear.
The study involved 10,745 pregnant women over 18 years old, with 9,102 samples included in the final analysis. Blood samples were collected between 17 days and 22 weeks of pregnancy.
Scientists extracted RNA (a molecule similar to DNA used to produce proteins) from the maternal blood and developed a predictive test. The blood test reportedly identified 91% of pregnancies at risk of developing premature preeclampsia in women aged 35 and over without pre-existing high-risk conditions, several months before symptoms emerged.
maneesh Jain, co-founder and CEO of Mirvie, the company planning to market the blood test, stated, “Like the revelation of molecular subtypes of breast cancer has led to better results, the discovery of molecular subtypes in preeclampsia offer a promising future for the personalization of pregnancy care and the fight against increasing birth rates with complications.”
The clinically validated blood test is expected to be available soon in the United States under the brand name Crossass™. Its arrival in Europe may follow if its performance is confirmed.
Blood Test Shows Promise in Predicting Preeclampsia: Your Questions Answered
Are you curious about preeclampsia and the latest advancements in it’s detection and prediction? This article delves into a promising new blood test, answering common questions in a clear, concise, and informative Q&A format.
What is Preeclampsia?
What is preeclampsia?
Preeclampsia is a serious medical condition that can occur during pregnancy. It’s characterized by high blood pressure and elevated protein levels in the urine. This can pose a critically important risk to both the mother and the unborn child, making it a medical emergency.
Why is early detection of preeclampsia significant?
Early detection is crucial because it allows for timely intervention and management, which can significantly improve outcomes for both the mother and the baby. This may include close monitoring, medication and in severe cases, premature delivery.
The New blood Test: Unveiling the Science
How does this new blood test predict preeclampsia?
This new blood test analyzes a molecular signal in a pregnant woman’s blood sample.Scientists extract RNA, a molecule similar to DNA, from the blood. This RNA is then used to develop a predictive test. The test looks for specific signatures that can indicate an increased risk of developing preeclampsia.
At what stage of pregnancy is this blood test administered?
The blood samples for this test are collected between 17 and 22 weeks of pregnancy.
How accurate is this blood test in predicting preeclampsia?
The blood test reportedly identified 91% of pregnancies at risk of developing premature preeclampsia in women aged 35 and over without pre-existing high-risk conditions.
What does it mean for a blood test to be “clinically validated?”
Clinically validated means that the test has been rigorously tested and proven to be accurate and reliable in a clinical setting.
Key features and Benefits
What are the advantages of this new blood test?
The article highlights the following potential benefits:
Early Prediction: The test can predict the risk of preeclampsia months before symptoms appear.
Improved Pregnancy Care: The test offers a promising future for the personalization of pregnancy care.
Who might benefit most from this blood test?
while not explicitly stated in the article, the test showed promising results in women aged 35 and over without pre-existing high-risk conditions.Though, further information from medical professionals should be considered.
Availability and future Outlook
When and where will this blood test be available?
The clinically validated blood test is expected to be available soon in the United States under the brand name crossass™. Its arrival in Europe may follow if its performance is confirmed.
What is the company behind this blood test?
The company planning to market the blood test is Mirvie.
What’s the significance of this test’s progress?
According to Maneesh Jain, co-founder and CEO of Mirvie, the revelation of molecular subtypes in preeclampsia offers a promising future for the personalization of pregnancy care.
What type of information does this blood test provide for the doctors and patients?
The value of a predictive blood test provides the following:
Earlier identification of women at risk for preeclampsia.
Enables Obstetricians a proactive approach for women at risk to get additional monitoring and treatment to improve outcomes for the mother and the baby.
* Personalized care options and proactive management of preeclampsia risks.
Summary Table
Here is a summary of key information about the new blood test:
| Feature | Details |
|---|---|
| Purpose | Predicts the risk of preeclampsia during pregnancy. |
| Technology | Analyzes RNA extracted from maternal blood. |
| Pregnancy Stage | samples collected between 17 and 22 weeks. |
| accuracy | Reportedly identifies 91% of those at risk of premature preeclampsia in those aged 35+ without existing risk factors. |
| Company | Mirvie |
| Availability | Expected soon in the US under the brand name Crossass™, with potential for later European release. |
Disclaimer
This information is based on the provided article and is not a substitute for professional medical advice. Always consult with your healthcare provider for any health concerns or before making any decisions related to your health or treatment.